Turn this list into pipeline.
Pharmaceuticals Companies in Birmingham: 300+ Active Firms (2026)
Pharmaceutical companies in Birmingham develop, manufacture, import or distribute regulated medicines across the West Midlands market.
Purchasing sits across regulatory affairs, quality, manufacturing operations, commercial supply and finance rather than a single buyer. Birmingham-area suppliers in this cohort usually sell into healthcare providers, research organisations, wholesalers, pharmacy channels and other business counterparties, with public-sector access shaping part of the route to market. Engagements tend to be operationally material rather than self-serve: recurring wholesale supply, batch manufacturing, import and release arrangements, or regulatory support linked to licence, authorisation and pharmacovigilance duties. The better-qualified buyers are lean or mid-sized operators with measurable UK revenue and a visible compliance function, not shell entities around dormant intellectual property.
Read more
Birmingham has 384 actively trading pharmaceutical firms, giving the city a sizeable but still specialised base within the West Midlands medicines market. Reported headcount across the cohort totals 475 people, which points to a long tail of lean distributors, licence holders and specialist service-led operators rather than a labour-heavy manufacturing cluster. Revenue scale is uneven: 20 firms report turnover above £5M, while the rest appear to sit below that threshold or are at an earlier commercial stage. A further 116 were incorporated since 2022, so the cohort mixes established regulated operators with newer market entrants still building authorisations, contracts and quality systems.
Human medicines sit inside an activity-based licensing regime overseen by the MHRA. Manufacturing, assembly and import work require the relevant manufacturer’s licence, evidence of good manufacturing practice and readiness for site inspection. Wholesale supply beyond supply directly to the patient brings wholesale distribution licensing and good distribution practice duties. Marketing authorisation, clinical trial approval and pharmacovigilance obligations shape the commercial path after development, while public healthcare access is filtered through cost-effectiveness review. The ABPI remains the main trade body for research-based pharmaceutical firms, but compliance exposure depends on the precise role each business plays in the medicines chain.
Birmingham’s pharmaceutical base appears more weighted towards lean regulated operators than towards large integrated manufacturers. That shape tends to favour specialist distribution, licence-holding, import, quality and commercial-access work, with development activity needing partners outside the immediate city market. Compliance costs may keep new entrants relatively selective about the activities they take on, particularly where inspection readiness, pharmacovigilance or public reimbursement evidence is involved. Consolidation pressure is likely to come less from headline research pipelines and more from operators seeking broader authorisations, dependable supply routes and closer links with pharmacy, wholesale and healthcare channels.
384
Active firms
2026
20
Above £5M
reported revenue
116
Since 2022
new incorporations
Key facts
About 5% of the trading cohort reports turnover above £5M (20 of 384 firms) — the rest sits below that revenue band.
30% of the cohort was incorporated since 2022 (116 firms), so a sizeable share is in its first few filing cycles.
Human medicines are regulated by the MHRA, which sets standards, evaluates new treatments, approves clinical trials, licenses medicines and oversees pharmacovigilance.
Manufacturing, assembly and import of human medicines require an MHRA manufacturer’s licence, good manufacturing practice compliance and regular site inspections.
Wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance.
UK business enterprise pharmaceutical R&D was £9.0 billion in 2022, equal to 0.36% of GDP and 18% of all UK business R&D.
UK pharmaceutical exports were £25.6 billion in 2023, with the UK ranked tenth among comparator countries for this metric.
Top Birmingham pharmaceuticals companies
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsManufactures bespoke “specials” medicines and cannabis‑based products for medicinal use (CBPMs), formulated for patients or animals with specific clinical needs. Also provides manufacturing,…
Serves UK healthcare and veterinary customers, including clinicians, pharmacies and organisations managing patients or animals with special clinical needs for bespoke unlicensed medicines and CBPMs.
Financial Health
StrongStrong · Growing, Hiring · 43% CAGR over 4y
Location
STERLING PHARMACEUTICALS LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsResearches, develops, manufactures and tests pharmaceutical products. Operates R&D and manufacturing facilities producing medicines for commercial customers, with products manufactured and quality…
Serves pharmaceutical and healthcare-sector customers worldwide, including organisations that buy EU GMP-compliant medicines and related manufacturing or testing support.
Financial Health
HealthyHealthy · -2% CAGR over 3y
Location
QUEST PHARM LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong
Location
QUEST HEALTHCARE ASEPTICS LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
ASSIGN MEDICARE LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsManufactures and markets pharmaceutical medicines across therapeutic areas including cardiovascular, anti‑infective and diabetes treatments. Conducts research and development, produces drugs in…
Serves B2B pharmaceutical buyers, distributors and strategic partners in domestic and international markets, including customers across Asia, Africa, Europe and the Americas.
Financial Health
WeakWeak · -2% CAGR over 4y
Location
GABO PHARMACEUTICALS LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsExports and wholesales UK‑manufactured medicines, vitamins, supplements, and medical supplies. Distributes prescription drugs, generic medicines, and over‑the‑counter pharmacy products to pharmacies,…
Serves retail pharmacies, pharmaceutical wholesalers, hospitals, doctors’ surgeries, healthcare providers and NGOs, mainly as B2B customers across the UK and international markets, including clinical…
Financial Health
StableStable
Location
Mediheath Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsSupplies pharmaceuticals and healthcare products to independent retail pharmacies through an online ordering platform, providing purchasing and account management services with same‑day and next‑day…
Serves independent retail pharmacy buyers and pharmacy businesses needing online purchasing accounts and delivery services.
Financial Health
HealthyHealthy · -42% CAGR over 2y
Location
Skylark Services Limited
Trajectory
5y · 2019–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
JNSF PHARMA LIMITED
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
StableStable
Location
313 PHARMA LTD
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
WeakWeak
Location
SIX WAYS BIRMINGHAM LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong · Hiring · 11% CAGR over 4y
Location
Medical Relief Consultancy Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · 0% CAGR over 4y
Location
Vertex Pharmaceuticals
Develops and commercialises prescription medicines for serious diseases, including cystic fibrosis, sickle cell disease and beta thalassemia. Conducts biomedical research, runs clinical trials, and…
Serves patients and healthcare professionals involved in serious diseases, including cystic fibrosis, sickle cell disease, beta thalassemia, kidney disease, pain and type 1 diabetes.
Location
WELLBEING PRODUCTS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · 0% CAGR over 4y
Location
GLOBEPHARMA LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StableStable · -90% CAGR over 2y
Location
Ahsa Health Limited
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
StableStable
Location
INTERCHEM (CHEMIST WHOLESALE) LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · -24% CAGR over 4y
Location
MASH PHARMACEUTICALS LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed
Location
CLOUD 9 MEDICAL LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed
Location
PHARMVISION LIMITED
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
Wave Life Sciences
Develops RNA‑based therapeutics using proprietary chemistry and RNA‑targeting technologies. Conducts research, clinical development and manufacturing of medicines for genetic and metabolic diseases…
Serves patients and families affected by serious rare and common diseases, including Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease and obesity, plus healthcare and…
Location
Mesox Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StableStable · Hiring · 145% CAGR over 2y
Location
Isha's Locum Services Limited
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
HealthyHealthy · 0% CAGR over 1y
Location
VITABONNA DEVELOPMENT LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Better Call Paul Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · 0% CAGR over 2y
Location
Medosphere Ltd
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
StableStable
Location
QUEST HC LIMITED
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
WeakWeak
Location
Healthcare Supplies (HS) Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
EPANGEA MEDICAL IMPORT AND EXPORT LTD
Trajectory
1y · 2025–NowFinancial Health
Insufficient historyInsufficient history
Location
MIRZYME THERAPEUTICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops diagnostics and therapeutics for pregnancy complications, particularly preeclampsia. Uses blood test data and a digital diagnostic algorithm to predict risk during pregnancy and is…
Targets pregnant women at risk of preeclampsia or fetal growth restriction, as well as clinicians, maternity care providers and healthcare systems involved in prenatal care.
Financial Health
DistressedDistressed · -62% CAGR over 4y
Location
SYNERGY SPECIALS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · 0% CAGR over 4y
Location
OmniOne Technologies Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
StableStable
Location
UNITECH SOLUTIONS U.K LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
10MILESGREEN LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed · 0% CAGR over 1y
Location
AKRON HEALTHCARE LTD
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsManufactures pharmaceutical formulations and hospital consumable chemicals, including soda lime CO2 absorbent, water purification and chlorine tablets, NaDCC disinfectant tablets, formaldehyde…
Sells to hospitals and medical buyers, government agencies, disaster-relief organisations, and consumers using water disinfection or household sterilisation products.
Financial Health
WeakWeak
Location
Avis Healthcare Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · -16% CAGR over 4y
Location
Mirage Distribution Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsWholesale supplier of pharmaceutical and healthcare products. Procures, parallel imports, licences, relabels and distributes branded and generic medicines, medical devices, diagnostics and…
Serves B2B customers in the UK pharmaceutical and healthcare supply chain, including large pharmacy chains, full- and short-line wholesalers, manufacturers and healthcare companies, with a retail…
Financial Health
StableStable · Hiring · 7% CAGR over 4y
Location
C.S.T. PHARMA GROUP HOLDINGS LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsOperates a group of companies engaged in wholesale distribution of pharmaceuticals, medical devices, medicines, and health and beauty products, including parallel import and repackaging, supplying…
Serves B2B customers across pharmaceutical and healthcare sectors, including the NHS, private healthcare providers, independent clinics, pharmacies, medical and beauty clinics, and aesthetics…
Financial Health
DistressedDistressed · -78% CAGR over 3y
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsResearches, develops, manufactures and sells pharmaceutical products and medical devices. Produces healthcare treatments and related products intended for use by healthcare professionals and patients.
Serves a mix of healthcare professionals and patients, with pharmaceutical and medical-device related audiences in the UK and internationally.
Financial Health
StrongStrong · Growing, Hiring · 18% CAGR over 1y
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops, manufactures, licenses and commercialises pharmaceutical products, including generic and specialty medicines. Operates R&D pipelines and partnerships to supply therapies such as oncology…
Serves healthcare providers, patients and pharmaceutical partners across global markets, with emphasis on oncology, immunology and other specialty medicine areas.
Financial Health
StableStable · -11% CAGR over 1y
Location
Trion Pharma Limited
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsWholesale distributor of pharmaceutical products and medical devices. Supplies medicines across therapeutic areas including dermatology, diabetes, gynaecology, ophthalmology, respiratory care,…
Sells B2B to pharmacies, hospitals and other healthcare providers, and partners with pharmaceutical companies, distributors and innovators. Targets UK, European and international healthcare markets…
Financial Health
StrongStrong · Hiring · 34% CAGR over 2y
Location
AVANTGARDE PHARMA LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures pharmaceutical products for human use. Operates production facilities, manages quality processes, and exports medicines to distributors and agents, supplying healthcare…
Sells to consumers needing human pharmaceutical therapies, and also serves B2B channel partners including distributors and agents involved in bringing medicines to market.
Financial Health
StableStable · -67% CAGR over 4y
Location
ADM Healthcare Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides specialty pharmaceuticals, medical devices and blood products, focusing on rare diseases and conditions in areas such as cardiovascular, central nervous system, diabetes and…
Serves pharmaceutical and medtech partners and healthcare stakeholders in specialty pharmaceuticals, rare diseases, medical devices and areas including cardiovascular, CNS, diabetes, diagnostics and…
Financial Health
StrongStrong · Growing, Hiring · 15% CAGR over 2y
Location
C.S.T. PHARMA LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsProcures and wholesales pharmaceutical products to businesses in the healthcare and pharmaceutical sectors, supplying medicines and related goods to pharmacies, hospitals, and distributors within the…
Serves B2B customers operating in the UK pharmaceutical and healthcare sectors, including organisations sourcing pharmaceutical goods.
Financial Health
StableStable · -80% CAGR over 3y
Location
Acetherix Healthcare Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed
Location
Agbor Eben & Co Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · 0% CAGR over 2y
Location
PHOENIX DISTRIBUTION SERVICES (UK) LIMITED
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDistributes pharmaceutical products and medical supplies to pharmacies, dispensing practices, and outpatient sites. Operates pharmacy branches and provides pharmaceutical care, pharmacy support…
Serves UK healthcare customers, mainly community pharmacies, dispensing practices and outpatient sites, while also reaching consumer patients through managed pharmacy branches.
Financial Health
StrongStrong · Growing, Hiring · 15% CAGR over 2y
Location
UNIT MEDIC-AIDS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · -91% CAGR over 2y
Location
A.R.K. HEALTHCARE LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsManufactures active pharmaceutical ingredients (APIs), pharmaceutical intermediates, fine chemicals and nutraceutical ingredients. Provides API development and manufacturing with R&D, analytical…
Serves B2B pharmaceutical customers worldwide, especially generic and finished dosage manufacturers requiring APIs, intermediates, fine chemicals and nutraceutical inputs across regulated therapeutic…
Financial Health
DistressedDistressed · -20% CAGR over 2y
Location
EVOIQ International Ltd
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Unlock all 384 leads
Showing 50 of 384 — +334 more with verified decision-maker contacts, live data, and CRM sync.
How Birmingham pharmaceuticals companies work and how to sell to them
What they do
Birmingham pharmaceutical firms tend to earn from regulated product supply, margin on wholesale distribution, batch-based manufacturing or assembly fees, import and release work, and retained regulatory or quality support. Commercial models are usually tied to licences, authorisations and repeat supply rather than low-touch subscriptions. Pricing often follows product margin, per-batch charges, service retainers, milestone fees or annual supply agreements. The service shape is practical: medicines, regulated handling, documentation, quality assurance, pharmacovigilance support and access to compliant supply routes. For sellers, the useful distinction is whether a prospect controls product rights, moves product through the supply chain, or provides specialist services around someone else’s medicine.
Who they sell to
Most sell to organisational buyers rather than consumers, including healthcare providers, pharmacy channels, wholesalers, research organisations and other pharmaceutical counterparties. Buying committees often include regulatory affairs, quality, operations, finance and commercial supply, with senior sign-off where licence exposure or product continuity is involved. Contracting is typically direct and relationship-led, sometimes shaped by public-sector procurement or framework-style access. Sales cycles can be longer where qualification, technical review, audits or pharmacovigilance duties are part of supplier approval. Smaller engagements may start with a defined service or limited product line, then expand once documentation, quality performance and supply reliability have been tested.
What they buy
Most pharmaceutical firms tend to spend on systems and services that protect licence status, product traceability and audit readiness. Useful categories include quality management software, document control, batch record systems, pharmacovigilance tooling, regulatory intelligence, customer relationship management, finance and inventory systems, secure cloud hosting, cyber security, analytics and controlled logistics support. Service spend often sits with regulatory consultants, validation specialists, legal advisers, accountants, recruitment firms and technical contractors. Manufacturing or distribution-led operators may also buy facilities maintenance, calibration, temperature monitoring, packaging, lab services and training. Messaging should connect the category to inspection evidence, fewer manual hand-offs, better release control or clearer commercial reporting.
Why and how to sell to them
Pharmaceutical buyers tend to evaluate vendors when a licence application, inspection, new product line, import arrangement, wholesale expansion or public healthcare tender exposes gaps in process control. Other triggers include a finance hire, a quality lead joining, turnover moving beyond founder-led administration, or a move from ad hoc supply into repeat contracts. Outbound that works is usually specific to the buyer’s role in the medicines chain: reducing audit preparation for quality teams, improving stock and margin visibility for finance, shortening documentation cycles for operations, or lowering compliance friction for regulatory affairs. Generic growth language is less persuasive than evidence of controlled implementation, traceability and sector familiarity.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Birmingham
Related directories
Frequently asked questions
How many pharmaceuticals companies are there in the Birmingham?↓
What counts as a pharmaceuticals company in this list?↓
Which are the largest pharmaceuticals companies in the Birmingham?↓
What do pharmaceuticals companies in the Birmingham actually do?↓
How does Birmingham pharmaceuticals compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical pharmaceuticals companies in the Birmingham?↓
Are these mostly new or established pharmaceuticals companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 384 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.